- 专利标题: PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION
-
申请号: US17542358申请日: 2021-12-03
-
公开(公告)号: US20220096527A1公开(公告)日: 2022-03-31
- 发明人: Xingchun HAN , Hassan JAVANBAKHT , Henrik MUELLER , Yongguang WANG , Song YANG
- 申请人: HOFFMANN-LA ROCHE INC.
- 申请人地址: US NJ Little Falls
- 专利权人: HOFFMANN-LA ROCHE INC.
- 当前专利权人: HOFFMANN-LA ROCHE INC.
- 当前专利权人地址: US NJ Little Falls
- 优先权: EP16175045.0 20160617
- 主分类号: A61K31/7125
- IPC分类号: A61K31/7125 ; C12Q1/6883 ; C12N15/113 ; C12Q1/70 ; A61P31/14 ; A61K31/4745 ; A61K31/519 ; C07K16/40 ; A61P31/20
摘要:
The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits hepatitis B virus (HBV) infections. The compound (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; and is identified as a compound that prevents, ameliorates and/or inhibits HBV infections. An inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing HBV infections; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of HBV infections is also provided. The present invention includes a 10-pharmaceutical composition for use in treatment and/or prevention of HBV infections, and a method for monitoring therapeutic success during treatment of HBV infections.